Nextech Invest

Oncology-focused VC, deep expertise

Profile being verified

Stage
A–B
Ticket
5–30M
Location
Zurich

What they look for

An oncology-focused VC, where the scientific expertise of the reference partner is decisive. They look at clinical data, endpoints, and potential licensing deals with big pharma.

What puts them off

Insufficient preclinical data, no defined CMC, unrealistic clinical timeline.

How to approach them

Via oncology Key Opinion Leaders (KOLs) or the Swiss big pharma network. Highly specialised.

Decision process

3–6 months of in-depth scientific due diligence.

Recent investments

Oncology biotech in Phase I–II, focus on immuno-oncology and ADCs.